SCHEMBL15712902

SCHEMBL15712902

O=C(O)c1cc(Cl)ccc1Nc1ccc2c(ccn2-c2ccc(F)cc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPO P05164 2/20 0.49
DHODH Q02127 2/20 0.45
EPHX2 P34913 1/20 0.45
MEN1 O00255 2/20 0.44
LMNA P02545 2/20 0.44
KMT2A Q03164 2/20 0.44
GRIK1 P39086 1/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
KCNH2 Q12809 4/20 0.42
AKR1C3 P42330 2/20 0.42
AKR1C2 P52895 2/20 0.42
SERPINE1 P05121 2/20 0.41
HPGD P15428 1/20 0.40
GFER P55789 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 1/20 0.39
HSD17B10 Q99714 1/20 0.39
P2RX1 P51575 1/20 0.39
ROCK2 O75116 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15712224 0.93 MEN1 (0.50) MPODHODHMEN1LMNAKMT2A
SCHEMBL15712311 0.90 DHODH (0.54) MPODHODHMEN1LMNAKMT2A
SCHEMBL15712742 0.89 ALDH1A1 (0.43) MPOEPHX2MEN1LMNAKMT2A
SCHEMBL15712432 0.87 ALDH1A1 (0.45) MPODHODHMEN1LMNAKMT2A
SCHEMBL15712338 0.87 DHODH (0.49) MPODHODHMEN1LMNAKMT2A
SCHEMBL15712830 0.84 MPO (0.66) MPODHODHMEN1LMNAKMT2A
SCHEMBL15712741 0.83 MPO (0.47) MPODHODHMEN1LMNAKMT2A
SCHEMBL15712227 0.82 DHODH (0.49) MPODHODHMEN1LMNAKMT2A
SCHEMBL15712223 0.82 MEN1 (0.45) MPODHODHMEN1LMNAKMT2A
SCHEMBL15712310 0.80 DHODH (0.46) MPODHODHMEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2915804-B1 NOVEL AMINE DERIVATIVE OR SALT THEREOF AS TNF ALPHA INHIBITORS FUJIFILM TOYAMA CHEMICAL CO LTD (JP) 2019-03-27 EP disclosed
US-9624215-B2 Amine derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2017-04-18 US disclosed
US-9624215-B2 Amine derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2017-04-18 US disclosed
US-20150299189-A1 NOVEL AMINE DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2015-10-22 US disclosed
US-20150299189-A1 NOVEL AMINE DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2015-10-22 US disclosed
EP-2915804-A1 NOVEL AMINE DERIVATIVE OR SALT THEREOF Toyama Chemical Co., Ltd. (JP) 2015-09-09 EP disclosed
EP-2915804-A1 NOVEL AMINE DERIVATIVE OR SALT THEREOF Toyama Chemical Co., Ltd. (JP) 2015-09-09 EP disclosed
WO-2014069510-A1 NOVEL AMINE DERIVATIVE OR SALT THEREOF 富山化学工業株式会社 (JP) 2014-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299189-A1 NOVEL AMINE DERIVATIVE OR SALT THEREOF HRH4, CLIC4, KRT18 MPO 607/4885DHODH 1568/4885EPHX2 2250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.